PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2172248
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2172248
AI Medical Device Lifecycle Assurance market size was valued at US$ 1,005.4 Million in 2025, expanding at a CAGR of 13.8% from 2026 to 2033.
AI medical device lifecycle assurance involves continuous activities that make sure that AI-powered medical devices are both safe and effective throughout their lifecycle. These include validation, evaluation, and monitoring of AI medical devices to reduce risks such as bias, drift, and degradation. This process involves a quality management system, real-world data analysis, and continuous validation in order to make sure that the AI medical devices are trustworthy. Regulatory bodies require the development of adaptable approaches to manage the changes in AI algorithms. These ensure the accuracy, transparency, and safety of the AI medical devices. The lifecycle ensures that they are accurate, transparent, and safe to use. Thus, AI medical device lifecycle assurance ensures that the device is safe, accurate, and compliant throughout the development and real-world usage.
AI Medical Device Lifecycle Assurance Market- Market Dynamics
Increasing adoption of AI-enabled medical devices to propel market demand
Increasing adoption of AI-enabled medical devices means that medical device manufacturers and healthcare providers need to make sure they are capable of validating, monitoring, and regulating AI medical devices throughout their lifecycle. For instance, in March 2026, according to the European Commission, 94% of health care facilities within the EU have already adopted or are planning to adopt AI solutions. 23% of digital health companies in the EU are making investments in AI & machine learning technologies, whereas 20% are investing in generative AI. The most advanced technology was found to be diagnosis solutions that are enabled by AI technology, where the anticipated adoption by 2029 will be almost 80%. This information was derived based on the responses received from 300 health care facilities and 70 digital health companies. Therefore, there is a growing need for strong assurance throughout the lifecycle of AI due to its increasing use in healthcare.
The Global AI Medical Device Lifecycle Assurance market is segmented on the basis of Lifecycle Stage, Assurance Type, Device Type, Deployment Mode, End User, and Region.
Within the lifecycle stage segment of the AI Medical Device Lifecycle Assurance market, design and development assurance is an important component that enables the development of artificial intelligence-based medical devices to make sure that such devices are safe, quality, and performance-based. In addition, Design and Development Assurance makes sure that any risk posed by algorithms, data quality, and model unreliability related to artificial intelligence is taken care of in order to advance into verification and validation phases. In February 2025, DEKRA SE introduced the latest Digital Trust Service, which integrates AI validation, cybersecurity, and functional safety testing to develop certified AI-enabled products. Hence, early-stage validation services are vital for building trustworthy, compliant AI medical devices.
AI-enabled diagnostic devices represent a significant category in the AI Medical Device Lifecycle Assurance market because of the use of such devices for the diagnosis and analysis of diseases as well as the need to assure their accuracy, reliability, safety, and regulatory compliance throughout the lifecycle of the device. In July 2025, the BSI group performed the 50th review of AI systems in accordance with the EU Medical Devices Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR). This was done in an effort to ensure that the AI-powered medical devices were safe and effective and complied with the regulations. Therefore, regulatory reviews are key in ensuring safe and compliant AI diagnostic devices.
AI Medical Device Lifecycle Assurance Market- Geographical Insights
North America holds a key position in the AI Medical Device Lifecycle Assurance market due to the advanced healthcare infrastructure, a strong AI innovation ecosystem, and an established regulatory framework for medical devices. For instance, in May 2026, according to The Commonwealth Fund, the U.S. spent 18% of its GDP on healthcare spending in 2014, which is double the average spent by OECD members. According to the report, the US has 3 hospital beds per 1,000 people, while the OECD average is 4.3 hospital beds and 8.6 medical school graduates per 100,000 people, in comparison to nearly 15 in the OECD countries. It should be noted that roughly 100 million people in the US, who form one-third of the US population, have no access to a usual source of care in terms of primary care, highlighting gaps in healthcare infrastructure and accessibility.
The AI Medical Device Lifecycle Assurance market around the globe is moderately competitive because the service providers offer services for AI model validation as well as for clinical safety, compliance, cybersecurity, and monitoring. The firms operating in the field of digital engineering, testing, and assurance services for medical devices include Accenture plc, Wipro Limited, Capgemini SE, Bureau Veritas SA, and Eurofins Scientific SE. In June 2026 Accenture agreed to acquire Alfahealth, a subsidiary of the Engineering Group, which would enhance its digital health offering in Italy. This acquisition would help improve clinical processes, link health data, and provide patient access, supporting the development of digital healthcare services and transformation initiatives.
In April 2026, Wipro reported an engagement with a major global medical technology company to improve post-market surveillance (PMS) using artificial intelligence. This will improve the capture and prioritization of reports to health authorities, improving compliance and efficiency across post-approval medical device activities.